Int J Stomatol ›› 2022, Vol. 49 ›› Issue (4): 441-447.doi: 10.7518/gjkq.2022081

• Reviews • Previous Articles     Next Articles

Research progress on the relationship between vitamin D and medication-related osteonecrosis of the jaw

Ji Xiao(),Zhu Guiquan.()   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2022-01-17 Revised:2022-04-02 Online:2022-07-01 Published:2022-06-28
  • Contact: Guiquan. Zhu;
  • Supported by:
    Central Guidance for Local Science and Technology Development Projects of Science and Technology Department of Sichuan Province(2020ZYD033)


Medication-related osteonecrosis of the jaw (MRONJ) is a complication during or after the use of antiresorptive or antiangiogenic agents. It has many risk factors, but the specific pathogenesis and effective treatment remain unclear. Vitamin D is closely related to oral and systemic health, and recent research has focused on the relationship between vitamin D and MRONJ. Studies found that the occurrence of MRONJ may be related to vitamin D deficiency. The high-risk populations for MRONJ appear to overlap with those with inadequate vitamin D levels. Moreover, the mechanism of MRONJ may involve the interaction of related drugs and vitamin D deficiency in the damage process of calcium homeostasis and immune function. Therefore, vitamin D may be effective means of combating MRONJ. This article reviewed the recent research progress on the relationship between vitamin D and MRONJ.

Key words: medication-related osteonecrosis of the jaw, vitamin D, bisphosphonates

CLC Number: 

  • R 78

1 Ruggiero SL, Dodson TB, Fantasia J, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
2 Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2007, 65(3): 369-376.
3 苏程, 王泽坤, 骆南羽, 等. 药物相关性颌骨坏死的研究进展[J]. 国际口腔医学杂志, 2017, 44(2): 228-234.
Su C, Wang ZK, Luo NY, et al. Research progress on medication-related osteonecrosis of the jaw[J]. Int J Stomatol, 2017, 44(2): 228-234.
4 Lorenzo-Pouso AI, Pérez-Sayáns M, García A, et al. Vitamin D supplementation: hypothetical effect on medication-related osteonecrosis of the jaw[J]. Med Hypotheses, 2018, 116: 79-83.
5 郭陟永, 刘济远, 李春洁, 等. 药物相关性颌骨坏死发病机制的研究进展[J]. 国际口腔医学杂志, 2020, 47(6): 717-724.
Guo ZY, Liu JY, Li CJ, et al. Research progress on the pathogenesis of medication-related osteonecrosis of the jaw[J]. Int J Stomatol, 2020, 47(6): 717-724.
6 Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, rando-mized trial[J]. J Clin Oncol, 2020, 38(26): 2971-2980.
7 Cha YH, Hong N, Rhee Y, et al. Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw[J]. Osteoporos Int, 2018, 29(4): 987-992.
8 姜钧健, 何悦. 药物相关性颌骨坏死治疗方法的研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(5): 474-477.
Jiang JJ, He Y. Research progress on treatment of medication-related osteonecrosis of the jaw[J]. China J Oral Maxillofac Surg, 2020, 18(5): 474-477.
9 Leizaola-Cardesa IO, Aguilar-Salvatierra A, Gonzalez-Jaranay M, et al. Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link[J]. Med Oral Patol Oral Cir Bucal, 2016, 21(2): e236-e240.
10 Ma SL, Tian XY, Wang YQ, et al. Vitamin D supplementation prevents placental ischemia induced endothelial dysfunction by downregulating placental soluble FMS-like tyrosine kinase-1[J]. DNA Cell Biol, 2017, 36(12): 1134-1141.
11 Brüggmann D, Alafi A, Jaque J, et al. World-wide research architecture of vitamin D research: density-equalizing mapping studies and socio-economic ana-lysis[J]. Nutr J, 2018, 17(1): 3.
12 廖祥鹏, 张增利, 张红红, 等. 维生素D与成年人骨骼健康应用指南(2014年标准版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1011-1030.
Liao XP, Zhang ZL, Zhang HH, et al. Application guideline for vitamin D and bone health in adult Chinese (2014 standard edition)[J]. Chin J Osteopor, 2014, 20(9): 1011-1030.
13 Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention[J]. Rev Endocr Metab Disord, 2017, 18(2): 153-165.
14 Grant WB, Boucher BJ. Randomized controlled trials of vitamin D and cancer incidence: a modeling study[J]. PLoS One, 2017, 12(5): e0176448.
15 Dalle Carbonare L, Mottes M, Valenti MT. Medication-related osteonecrosis of the jaw (MRONJ): are antiresorptive drugs the main culprits or only accomplices? the triggering role of vitamin D deficiency[J]. Nutrients, 2021, 13(2): 561.
16 陈俊敏. 二磷酸盐(唑来膦酸)治疗骨质疏松症引起不良反应与维生素D的相关性[D]. 银川: 宁夏医科大学, 2019.
Chen JM. Correlation between vitamin D and adverse reactions induced by diphosphate (zoledronic acid) in the treatment of osteoporosis[D]. Yinchuan: Ningxia Medical University, 2019.
17 Demircan S, Isler SC. Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: a case control study[J]. Niger J Clin Pract, 2020, 23(2): 154-158.
18 Heim N, Warwas FB, Wilms CT, et al. Vitamin D (25-OHD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2017, 45(12): 2068-2074.
19 Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population[J]. Eur J Cancer, 2005, 41(8): 1164-1169.
20 Badros A, Goloubeva O, Terpos E, et al. Prevalence and significance of vitamin D deficiency in multiple myeloma patients[J]. Br J Haematol, 2008, 142(3): 492-494.
21 Martelli FS, Martelli M, Rosati C, et al. Vitamin D: relevance in dental practice[J]. Clin Cases Miner Bone Metab, 2014, 11(1): 15-19.
22 Hokugo A, Christensen R, Chung EM, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats[J]. J Bone Miner Res, 2010, 25(6): 1337-1349.
23 Anderson PH, Sawyer RK, Moore AJ, et al. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model[J]. J Bone Miner Res, 2008, 23(11): 1789-1797.
24 Hakim SG, Bruecker CW, HChJacobsen, et al. The value of FDG-PET and bone scintigraphy with SPECT in the primary diagnosis and follow-up of patients with chronic osteomyelitis of the mandible[J]. Int J Oral Maxillofac Surg, 2006, 35(9): 809-816.
25 Liu PT, Stenger S, Li HY, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response[J]. Science, 2006, 311(5768): 1770-1773.
26 Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3 [J]. FASEB J, 2005, 19(9): 1067-1077.
27 Hansen TH, Madsen MTB, Jørgensen NR, et al. Bone turnover, calcium homeostasis, and vitamin D status in Danish vegans[J]. Eur J Clin Nutr, 2018, 72(7): 1046-1054.
28 Fan JX, Li N, Gong XF, et al. Serum 25-hydroxyvitamin D, bone turnover markers and bone mineral density in postmenopausal women with hip fractures[J]. Clin Chim Acta, 2018, 477: 135-140.
29 Kim WW, Chung SH, Ban EJ, et al. Is preoperative vitamin D deficiency a risk factor for postoperative symptomatic hypocalcemia in thyroid cancer patients undergoing total thyroidectomy plus central compartment neck dissection[J]. Thyroid, 2015, 25(8): 911-918.
30 Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture[J]. N Engl J Med, 2007, 357(18): 1799-1809.
31 Michalak F, Hnitecka S, Dominiak M, et al. Schemes for drug-induced treatment of osteonecrosis of jaws with particular emphasis on the influence of vitamin D on therapeutic effects[J]. Pharmaceutics, 2021, 13(3): 354.
32 Ardine M, Generali D, Donadio M, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic brea-st cancer patients to undergo osteonecrosis of the jaw[J]. Ann Oncol, 2006, 17(8): 1336-1337.
33 Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity[J]. Nat Clin Pract Endocrinol Metab, 2008, 4(2): 80-90.
34 康壮飞. 唑来膦酸对颌骨影响的基因差异分析[D]. 石家庄: 河北医科大学, 2016.
Kang ZF. The effect of mandibule on gene differential expression after using zoledronic acid[D]. Shijia-zhuang: Hebei Medical University, 2016.
35 陶船思博, 梅芳, 钟金晟. 滤泡样树突细胞分泌蛋白的自然免疫作用和在口腔组织中的表达[J]. 国际口腔医学杂志, 2014, 41(4): 444-447.
Tao CSB, Mei F, Zhong JS. Innate immune effect and its expression level in oral tissues of follicular dendritic cells secreted protein[J]. Int J Stomatol, 2014, 41(4): 444-447.
36 Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw[J]. Cancer Treat Rev, 2015, 41(5): 455-464.
37 Yazdi PM, Schiodt M. Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(4): 416-422.
38 Li H, Li B, Wang Q, et al. Attenuation of inflammatory response by 25- hydroxyvitamin D3-loaded po-lylactic acid microspheres in treatment of periodontitis in diabetic rats[J]. Chin J Dent Res, 2014, 17(2): 91-98.
39 Ramos-Martínez E, López-Vancell MR, Fernández de Córdova-Aguirre JC, et al. Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFNγ levels and cathelicidin expression[J]. Cytokine, 2018, 108: 239-246.
40 Saito M, Grynpas MD, Burr DB, et al. Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone[J]. Bone, 2015, 73: 8-15.
41 Catalano A, Morabito N, Atteritano M, et al. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis[J]. Calcif Tissue Int, 2012, 90(4): 279-285.
42 Xiong ZH, Wu JY, Liu ZJ, et al. Moderate osteoporosis itself is beneficial for bones[J]. Med Hypotheses, 2020, 134: 109427.
43 Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women[J]. Eur J Clin Pharmacol, 1996, 51(2): 145-147.
44 Soares AL, Simon S, Gebrim LH, et al. Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study[J]. Support Care Cancer, 2020, 28(5): 2265-2271.
[1] Guo Zhiyong,Liu Jiyuan,Li Chunjie,Tang Xiufa. Research progress on the pathogenesis of medication-related osteonecrosis of the jaw [J]. Int J Stomatol, 2020, 47(6): 717-724.
[2] Su Cheng, Wang Zekun, Luo Nanyu, Tang Hua.. Research progress on medication-related osteonecrosis of the jaw [J]. Inter J Stomatol, 2017, 44(2): 228-234.
[3] Tong Chunshi1, Zou Yongwei1, Wang Lei1, Gong Junxia2, Li Wenran1, Liu Changhuan1, Lu Jianzhong1.. Vitamin D and its relationship with periodontitis [J]. Inter J Stomatol, 2014, 41(4): 474-477.
[4] Su Meiying1, Shi Bin1, 2, Zhang Yufeng1, 2.. Influence of bisphosphonates on dental implants [J]. Inter J Stomatol, 2013, 40(5): 653-656.
[5] Shi Hui, Li Zhihua.. Research progress on the bisphosphonates in orthodontic therapy [J]. Inter J Stomatol, 2012, 39(4): 533-536.
Full text



[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .